<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02062008</url>
  </required_header>
  <id_info>
    <org_study_id>Combined PET-MRI</org_study_id>
    <nct_id>NCT02062008</nct_id>
  </id_info>
  <brief_title>Validation of Combined PET-MR Quantitative Parameters for Cardiac Applications</brief_title>
  <official_title>Validation of Combined PET-MR Quantitative Parameters for Cardiac Applications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to understand how simultaneous PET/MR acquisition can provide
      novel qualitative and quantitative biomarkers to guide clinical intervention and predict
      prognosis of patients with cardiovascular disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  To compare regional myocardial uptake of FDG on images obtained on a standard PET camera
           with the new PET/MR camera, in patients with coronary artery disease.

        -  To compare viability maps obtained with cardiac MR images and FDG-PET for delineation of
           myocardial infarct core and border zone, in patients with coronary artery disease.

        -  To correlate MRI myocardial strain with relative myocardial FDG uptake in patients with
           a previous myocardial infarction.

        -  To interrogate if simultaneous acquisition of cardiac PET and viability cardiac MR
           differ from acquisitions obtained independently, with special focus on attenuation
           correction methods

        -  To combined MRI scar map with FDG-PET uptake in patients with cardiac sarcoidosis and
           myocarditis.

        -  To correlate morphologic characteristics of atherosclerotic disease in the thoracic and
           abdominal aorta with FDG uptake and ferumoxytol enhancement, as a marker of
           inflammation.

        -  To evaluate cardiac strain and myocardial scar burden in obese patients with and without
           diabetes.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FDG uptake in SUVs (Standardized Uptake Values)</measure>
    <time_frame>2 hours</time_frame>
    <description>Correlation of combined PET/MR findings with independently acquired PET and MR data</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Cardiac Disease</condition>
  <arm_group>
    <arm_group_label>Cardiac patients receiving PET/MR</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>PET-MRI with intravenous Gadolinium and FDG. The entire study will take approximately one hour.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PET-MRI</intervention_name>
    <description>PET-MRI with intravenous Gadolinium and FDG. The entire study will take approximately one hour.</description>
    <arm_group_label>Cardiac patients receiving PET/MR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with ischemic and non-ischemic cardiac disease referred for cardiac PET for
             viability imaging.

        Exclusion Criteria:

          -  Contraindications for MRI, including cardiac pacemaker, claustrophobia, retained
             metallic foreign body, cochlear implant, Aneurysm clip in the brain, pregnancy and
             eGFR less than 45%.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen G Ordovas, MD,MAS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistent Professor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF University of California in San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karen G Ordovas, MD,MAS</last_name>
      <phone>415-476-1397</phone>
      <email>Karen.Ordovas@ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Miguel Pampaloni, MD</last_name>
      <email>Miguel.Pampaloni@ucsf.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Karen G Ordovas, MD, MAS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2014</study_first_submitted>
  <study_first_submitted_qc>February 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2014</study_first_posted>
  <last_update_submitted>October 1, 2014</last_update_submitted>
  <last_update_submitted_qc>October 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Positron Emission Tomography-Magnetic Resonance Imaging</keyword>
  <keyword>Cardiac Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

